[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100541218":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":34,"centralContacts":38,"locations":48,"responsibleParty":68,"collaborators":70,"id":74,"slug":42,"hasResults":75,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":75,"sex":81,"minAge":82,"maxAge":83,"enrollmentInfo":84,"targetDuration":42,"studyType":87,"phases":88,"briefSummary":90,"conditions":91,"keywords":94,"overallStatus":51,"whyStopped":42,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":105},{"fullName":5,"class":6},"University of California, Los Angeles","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Post-CABG patients with Thiamine Treatment Intervention.","EXPERIMENTAL","Assess cognition and evaluate blood thiamine, lactate, and inflammatory marker levels in patients receiving thiamine intervention treatment within 5 days (baseline) and one month after CABG.",[13],"Drug: Thiamine",{"label":15,"type":16,"description":17,"interventionNames":18},"Post-CABG patients without Thiamine Treatment Intervention.","PLACEBO_COMPARATOR","Assess cognition and evaluate blood thiamine, lactate, and inflammatory marker levels in patients receiving placebo treatment within 5 days (baseline) and one month after CABG.",[19],"Drug: Placebo",[21,28],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Thiamine","Participants will be given an infusion of thiamine.",[9],[27],"Vitamin B1",{"type":22,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"Placebo","Participants will be given an infusion of the placebo treatment.",[15],[33],"inactive",[35],{"name":36,"affiliation":5,"role":37},"Rajesh Kumar, PhD","PRINCIPAL_INVESTIGATOR",[39,44],{"name":36,"role":40,"phone":41,"phoneExt":42,"email":43},"CONTACT","310-206-1699",null,"rkumar@mednet.ucla.edu",{"name":45,"role":40,"phone":46,"phoneExt":42,"email":47},"Dineth Karunamuni, MS","856-701-5332","dkarunamuni@mednet.ucla.edu",[49],{"facility":50,"status":51,"city":52,"state":53,"zip":54,"country":55,"cosmosGeoPoint":56,"geoPoint":61,"contacts":62},"UCLA","RECRUITING","Los Angeles","California","90095","United States",{"type":57,"coordinates":58},"Point",[59,60],-118.24368,34.05223,{"lat":60,"lon":59},[63,66,67],{"name":64,"role":40,"phone":65,"phoneExt":42,"email":43},"Rajesh Kumar, PHD","310-825-1808",{"name":45,"role":40,"phone":46,"phoneExt":42,"email":47},{"name":64,"role":37,"phone":42,"phoneExt":42,"email":42},{"type":37,"investigatorFullName":36,"investigatorTitle":69,"investigatorAffiliation":5,"oldNameTitle":42,"oldOrganization":42},"Professor of Anesthesiology and Radiological Sciences",[71],{"name":72,"class":73},"National Institute on Aging (NIA)","NIH","100541218",false,"NCT06326996","Thiamine Intervention and Coronary Artery Bypass Grafting","Thiamine Intervention and Cognition in Older Adults Undergoing Coronary Artery Bypass Grafting - A Randomized Clinical Trial.","B1&CABG","Inclusion Criteria:\n\n* Patients with Coronary Heart Disease (CHD) scheduled for Bypass Grafting (CABG)\n* Thiamine deficiency before CABG\n* European System for Cardiac Operative Risk Evaluation II (EuroSCORE II) \\>1.5%\n* Off-pump surgery\n\nExclusion Criteria:\n\n* Dementia at baseline \\[Montreal Cognitive Assessment (MoCA) \\\u003C21 within 5 days before CABG\\]\n* Current in-take of thiamine\n* Known thiamine allergy\n* Uncontrolled blood glucose levels\n* Unable to give consent due to illness\n* History of hyperlactatemia\n* Recent (within several years and\u002For up to the judgment of the PI\u002Fco-PIs) cerebral incidents (seizure or head trauma resulting in loss of consciousness and\u002For concussion)\n* Stroke\n* Diagnosed psychiatric diseases (clinical depression, schizophrenia, manic-depression)\n* Patients with history of alcohol or substance abuse\n* Acute or chronic infections (tuberculosis, hepatitis, or encephalopathy)\n* Diagnosed neuro-degenerative diseases (Alzheimer's or Parkinson's disease)\n* Chronic immunodeficiency (including HIV)\n* Congenital brain deficits will also be excluded","ALL","60 Years","80 Years",{"count":85,"type":86},52,"ESTIMATED","INTERVENTIONAL",[89],"EARLY_PHASE1","The purpose of this study is to gain a better understanding of the association between brain changes and cognitive deficits in coronary heart disease (CHD) patients undergoing coronary artery bypass grafting (CABG) and whether a low-cost thiamine intervention can be used to reduce post-CABG cognitive issues in CHD subjects.",[92,93],"Coronary Heart Disease","Coronary Artery Bypass Grafting",[95],"thiamine intervention","2025-07-30",{"date":98,"type":99},"2025-08-01","ACTUAL",{"date":101,"type":99},"2024-10-10",{"date":103,"type":86},"2026-09-30",{"name":5,"class":6},1]